Antibiotic First-in-Class 0.5 CE Credits*

Blujepa

gepotidacin • 750 mg oral tablet

Manufacturer:
GSK
UTI approval:
March 2025
Gonorrhea approval:
December 2025

*Accreditation is pending through ACCME partnership. CE values on this page are for MVP demonstration and are not yet formally accredited.

0.5 CE Credits* • ~20 Minutes

Blujepa for UTI & Gonorrhea

0:00 20:00

Narrator: Welcome to MedEQ, your continuing education resource for the latest FDA-approved medications. In today's module, we'll cover Blujepa, known generically as gepotidacin, a first-in-class antibiotic that represents a significant advancement in the treatment of uncomplicated urinary tract infections and, more recently, uncomplicated urogenital gonorrhea.

Narrator: Blujepa was developed by GlaxoSmithKline and received its initial FDA approval in March 2025 for uncomplicated UTI. In December 2025, the FDA expanded the indication to include uncomplicated urogenital gonorrhea in patients with limited or no alternative treatment options.

Narrator: What makes Blujepa particularly noteworthy is its mechanism of action. Gepotidacin belongs to a new class called triazaacenaphthylene antibiotics. It works by binding to a unique site on bacterial DNA gyrase and topoisomerase IV, both essential enzymes for bacterial DNA replication. While fluoroquinolones also target these enzymes, gepotidacin binds at a completely different location, meaning cross-resistance with fluoroquinolones is unlikely. This is critical at a time when antibiotic resistance, including fluoroquinolone resistance in both UTI pathogens and N. gonorrhoeae, continues to rise globally.

Narrator: For prescribing, dosing differs by indication. For uncomplicated UTI, BLUJEPA is 1,500 milligrams per dose (two 750 mg tablets), taken twice daily about 12 hours apart for 5 days, after a meal. For uncomplicated urogenital gonorrhea, BLUJEPA is 3,000 milligrams (four 750 mg tablets), followed by a second 3,000 milligram dose about 12 hours later, after a meal. The food instruction is important for reducing gastrointestinal intolerance.

Narrator: Now, let's discuss the key safety considerations. First, QTc prolongation. Blujepa can cause clinically significant QTc prolongation. Avoid it in patients with a history of QTc prolongation, relevant cardiac disease, or those on antiarrhythmic agents or other QTc-prolonging medications.

Narrator: Second, renal function. Blujepa is contraindicated in patients with severe renal impairment (eGFR below 30). Increased drug exposure in these patients raises the risk of adverse cardiac effects. No dose adjustment is needed for moderate impairment.

Narrator: Third, drug interactions. Avoid concomitant use with strong CYP3A4 inhibitors such as clarithromycin, ketoconazole, and ritonavir. These increase gepotidacin levels and compound the QTc risk.

Narrator: And finally, as with all antibiotics, there's a risk of Clostridioides difficile infection. Counsel patients to report any persistent diarrhea.

Narrator: In summary, Blujepa represents the first new oral antibiotic class for UTI in decades. It's a valuable option particularly for patients with fluoroquinolone-resistant infections. Remember: check renal function, review the medication list for CYP3A4 inhibitors and QTc-prolonging drugs, and counsel patients to take it with food. Thank you for completing this MedEQ module.

Overview

Blujepa (gepotidacin) is a bactericidal, first-in-class triazaacenaphthylene antibiotic discovered by GSK scientists. It represents a novel mechanism of action in antimicrobial therapy — inhibiting bacterial DNA replication by targeting both DNA gyrase (topoisomerase II) and topoisomerase IV through a distinct binding site not shared by any other approved antibiotic.

This dual-target mechanism means Blujepa has a lower potential for development of antimicrobial resistance compared to existing antibiotic classes, making it a significant addition to the clinical armamentarium at a time when antibiotic resistance is a growing global concern.

Approved Indications

1. Uncomplicated Urinary Tract Infections (uUTI)

Blujepa is indicated for the treatment of uncomplicated UTI in female adult and pediatric patients aged 12 years and older weighing at least 40 kg. Susceptible organisms include:

  • Escherichia coli
  • Klebsiella pneumoniae
  • Citrobacter freundii complex
  • Staphylococcus saprophyticus
  • Enterococcus faecalis

2. Uncomplicated Urogenital Gonorrhea (uGC)

Blujepa is indicated in adult and pediatric patients aged 12 years and older weighing at least 45 kg who have limited or no alternative options for the treatment of uncomplicated urogenital gonorrhea caused by susceptible strains of Neisseria gonorrhoeae.

Note on Gonorrhea Indication

Approval is based on limited clinical safety data. This indication is specifically for patients with limited or no alternative treatment options. It is not recommended as empiric first-line therapy for gonorrhea.

Dosing & Administration

Indication Dose Frequency Duration Notes
Uncomplicated UTI 1,500 mg (2 x 750 mg tablets) Twice daily (~12 hours apart) 5 days Take after a meal
Urogenital gonorrhea 3,000 mg (4 x 750 mg tablets) 2 doses (~12 hours apart) Single-day regimen Take each dose after a meal

Blujepa should be taken after a meal to reduce the possibility of gastrointestinal intolerance. The tablet should be swallowed whole.

Contraindications & Warnings

QTc Prolongation

Avoid Blujepa in patients with a history of QTc interval prolongation, those with relevant pre-existing cardiac disease, patients taking antiarrhythmic agents, or other medications that may prolong the QTc interval. Blujepa can cause clinically significant QTc prolongation.

Severe Renal Impairment

Avoid use of Blujepa in patients with eGFR <30 mL/min/1.73m², including those receiving dialysis. Increased gepotidacin exposure in severe renal impairment raises the risk of QTc prolongation and other adverse effects.

Clostridioides difficile Infection (CDI)

CDI has been reported with nearly all systemic antibacterial agents including Blujepa. Severity ranges from mild diarrhea to fatal colitis. Evaluate patients who develop diarrhea during or after treatment.

Drug Interactions

CYP3A4 Inhibitors — Avoid Concomitant Use

Avoid concomitant use of Blujepa with strong CYP3A4 inhibitors. Co-administration increases gepotidacin plasma levels, raising the risk of QTc prolongation and other adverse effects.

Common strong CYP3A4 inhibitors to watch for:

  • Macrolide antibiotics: clarithromycin, erythromycin
  • Azole antifungals: ketoconazole, itraconazole, voriconazole
  • HIV protease inhibitors: ritonavir, lopinavir
  • Other: nefazodone, grapefruit juice (large quantities)

Mechanism of Action

Gepotidacin is a novel topoisomerase II inhibitor that binds to a unique site on bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. Unlike fluoroquinolones, which also target these enzymes, gepotidacin binds at a different location on the GyrA subunit. This distinct binding site means:

  • Cross-resistance with fluoroquinolones is unlikely
  • Dual-target activity provides a higher barrier to resistance development
  • The drug is bactericidal (kills bacteria rather than just inhibiting growth)

Clinical Trials

The UTI indication was supported by two Phase 3 trials (EAGLE-2 and EAGLE-3) in 3,136 adult and adolescent female patients, showing non-inferiority to nitrofurantoin at test-of-cure.

The gonorrhea indication was supported by Trial 3 (NCT04010539), where gepotidacin demonstrated non-inferiority to ceftriaxone plus azithromycin for microbiologic success at the urogenital site (92.6% vs 91.2% in the micro-ITT population).

Adverse Reactions by Indication

Adverse reaction rates are indication-specific and should be interpreted in that context.

  • uUTI (most common): diarrhea (16%), nausea (9%), abdominal pain (4%), flatulence (3%), headache (2%), soft feces (2%), dizziness (2%), vomiting (2%), vulvovaginal candidiasis (1%).
  • Uncomplicated urogenital gonorrhea (most common): diarrhea (49%), nausea (24%), abdominal pain (8%), vomiting (6%), flatulence (6%), dizziness (5%), soft feces (5%), headache (3%), fatigue (3%), hyperhidrosis (2%).

Antimicrobial Stewardship

To help limit antimicrobial resistance, BLUJEPA should be used for infections that are proven or strongly suspected to be caused by susceptible bacteria. Counsel patients to complete the full prescribed regimen and avoid unnecessary or incomplete antibiotic use.

Practical Prescribing Workflow

  1. Confirm indication and eligibility (including age and weight threshold by indication).
  2. Review renal function; avoid use in severe renal impairment (eGFR <30 mL/min/1.73m²).
  3. Review cardiac/QTc risk profile and concurrent QTc-prolonging therapies.
  4. Screen current medications for strong CYP3A4 inhibitors before prescribing.
  5. Select indication-specific regimen and verify meal-timing instructions with the patient.
  6. Provide fair-balance counseling on expected GI effects and warning symptoms.

Gonorrhea Use Constraints

  • Use for uncomplicated urogenital gonorrhea in patients with limited or no alternative treatment options.
  • Ensure patient can complete both doses approximately 12 hours apart on the same day.
  • Discuss common adverse reactions up front, especially diarrhea and nausea, to support completion of the second dose.

Clinical Pearls

  • Blujepa fills an important gap as the first new oral antibiotic class for UTI in decades
  • Particularly valuable for patients with fluoroquinolone-resistant UTIs
  • The gonorrhea indication is reserved for cases with limited alternatives — not first-line
  • Always check renal function and medication list before prescribing
  • No dose adjustment for moderate renal impairment (eGFR 30-89)
  • uUTI regimen is two 750 mg tablets twice daily for 5 days; gonorrhea regimen is two 3,000 mg doses 12 hours apart
  • Counsel patients to take each dose with food and complete the full prescribed regimen

References

Ready for Adaptive Case Practice?

Complete the adaptive assessment with uUTI and gonorrhea tracks, remediation checkpoints, and scenario-specific takeaways to strengthen prescribing decisions. CE values remain pending accreditation.

Start Assessment